Therapeutic strategies for treatment of pulmonary lymphangioleiomyomatosis

Bibliography

• McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012;186(12):1210-12
   PubMed Web of Science ®Google Scholar
• Henske EP, McCormack FX. Lymphangioleiomyomatosis—a wolf in sheep’s clothing. J Clin Invest 2012;122(11):3807-16
   PubMed Web of Science ®Google Scholar
• Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010;104(Suppl 1):S45-58
   PubMed Web of Science ®Google Scholar
• Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000;31(10):1242-8
   PubMed Web of Science ®Google Scholar
• Meraj R, Wikenheiser-Brokamp KA, Young LR, McCormack FX. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012;33(05):486-97
   PubMedGoogle Scholar
• Johnson SR, Cordier JF, Lazor R, et al. European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. European Respiratory ournal 2010;35(1):14-26
   PubMed Web of Science ®Google Scholar
• Cudzilo CJ, Szczesniak RD, Brody AS, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013;144(2):578-85
   PubMed Web of Science ®Google Scholar
• Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-d prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138(3):674-81
   PubMed Web of Science ®Google Scholar
• Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for Lymphangioleiomyomatosis. N Engl J Medic 2008;358(2):199-200
   PubMed Web of Science ®Google Scholar
• Young LR, Lee H-S, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial. Lancet 2013;1(6):445-52
   Web of Science ®Google Scholar
• Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 2002;277:30958-67
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002;11:525-34
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009;2(67):1-6
   Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358(2):140-51
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595-606
   PubMed Web of Science ®Google Scholar
• Hammes SR, Krymskaya VP. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM). Horm Cancer 2013;4:70-7
   PubMed Web of Science ®Google Scholar
• Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106(8):2635-40
   PubMed Web of Science ®Google Scholar
• Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173(1):105-11
   PubMed Web of Science ®Google Scholar
• Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004;126(6):1867-74
   PubMed Web of Science ®Google Scholar
• Gao L, Yue MM, Davis J, et al. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch 2014;464(4):495-503
   PubMed Web of Science ®Google Scholar
• Pan L-H, Ito H, Kurose A, et al. Pulmonary lymphangioleiomyomatosis: a case report with immunohistochemical details and DNA analysis. Tohoku JExpe Med 2003;199(2):119-26
   PubMed Web of Science ®Google Scholar
• Flavin RJ, Cook J, Fiorentino M, et al. beta-catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol 2011;135(5):776-82
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002;4:648-57
   PubMed Web of Science ®Google Scholar
• Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002;4:658-65
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol 2012;46(5):563-5
   PubMed Web of Science ®Google Scholar
• El-Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014;23(131):30-5
   PubMedGoogle Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12(1):21-35
   PubMed Web of Science ®Google Scholar
• Parkhitko A, Myachina F, Morrison TA, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci USA 2011;108(30):12455-60
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Fehrenbach M, et al. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 2012;4(154):154ra134
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Li H, et al. mTORC2 Is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 2011;31(12):2484-98
   PubMed Web of Science ®Google Scholar
• Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol 2009;625(1–3):220-33
   PubMed Web of Science ®Google Scholar
• Goncharova E, Goncharov D, Noonan D, Krymskaya VP. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 2004;167(6):1171-82
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Lim PN, et al. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;34:473-80
   PubMed Web of Science ®Google Scholar
• Demierre M-F, PeterHiggins DR, Gruber SB, et al. Statins and cancer prevention. Nature Reviews Cancer 2005;5(12):930-42
   PubMed Web of Science ®Google Scholar
• Lee N, Woodrum CL, Nobil AM, et al. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 2009;9(1):8
   PubMedGoogle Scholar
• Finlay G, Malhowski AJ, Polizzi K, et al. Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther 2009;8:1799-807
   PubMed Web of Science ®Google Scholar
• Atochina-Vasserman EN, Goncharov DA, Volgina AV, et al. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2–Null cell growth and signaling. Am J Respir Cell Mol Biol 2013;49(5):704-9
   PubMed Web of Science ®Google Scholar
• El-Chemaly S, Taveira-DaSilva A, Stylianou MP, Moss J. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 2009;34(2):513-14
   PubMed Web of Science ®Google Scholar
• Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated TTIMP-3 regulation. Am J Respir Cell Mol Biol 2003;28(5):546-50
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Kawamoto M, Yamamoto A, et al. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum Pathol 1990;21(12):1252-61
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of MMPs and TIMPs in pulmonary lymphangioleiomyomatosis. Hum Pathol 1997;28:1071-8
   PubMed Web of Science ®Google Scholar
• Lee P-S, Tsang SW, Moses MA, et al. Rapamycin-insensitive Up-regulation of MMP2 and Other Genes in TSC2-deficient LAM-like Cells. Am J Respir Cell Mol Biol 2009;42:227-34
   PubMed Web of Science ®Google Scholar
• Chang WYC, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production and adhesion in LAM related cells. Am J Physiol Lung Cell Mol Physiol 2010;299:L393-400
   PubMed Web of Science ®Google Scholar
• Moir LM, Ng HY, Poniris MH, et al. Doxycycline inhibits MMP. 2 secretion from TSC2-null MEFs and lymphangioleiomyomatosis cells. Br J Pharmacol 2011;164:83-92
   PubMedGoogle Scholar
• Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N England J Med 2006;354(24):2621-2
   PubMed Web of Science ®Google Scholar
• Chang WYC, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014;43(4):1114-23
   PubMed Web of Science ®Google Scholar
• Pimenta SP, Baldi BG, Kairalla RA, et al. Doxiciclina em pacientes com linfangioleiomiomatose: biomarcadores e resposta funcional pulmonar. J Bras Pneumol 2013;39:5-15
   PubMedGoogle Scholar
• Baldi BG, de Albuquerque AL, Pimenta SP, et al. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM. Respir Med 2013;107(11):1773-80
   PubMed Web of Science ®Google Scholar
• Crooks DM, Rodriguez GP, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101(50):17462-7
   PubMed Web of Science ®Google Scholar
• Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM. cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 2005;29:1356-66
   PubMed Web of Science ®Google Scholar
• Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38:376-81
   PubMed Web of Science ®Google Scholar
• Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167(7):976-82
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Spaits M, et al. Abnormal smooth muscle cell growth in. LAM: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006;34:561-72
   PubMed Web of Science ®Google Scholar
• Yeatman TJ. A renaissance for Src. Nature Reviews Cancer 2004;4:470-80
   PubMed Web of Science ®Google Scholar
• Tyryshkin A, Bhattacharya A, Eissa NT. Src kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res 2014;74(7):1996-2005
   PubMed Web of Science ®Google Scholar
• Holgate ST and Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008;8(3):218-30
   PubMed Web of Science ®Google Scholar
• Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome of lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001;164:1072-6
   PubMed Web of Science ®Google Scholar
• Ando K, Kurihara M, Kataoka H, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 2013;51(3):175-83
   PubMedGoogle Scholar
• Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006;9(2):77-9
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105(45):17414-19
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Yoon SO, Kim SG, et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012;485(7396):109-13
   PubMed Web of Science ®Google Scholar
• Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006;314(5798):467-71
   PubMed Web of Science ®Google Scholar
• Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;23(4):569-80
   Google Scholar
• Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10(11):868-80
   PubMed Web of Science ®Google Scholar
• Badri KR, Gao L, Hyjek E, et al. Exonic mutations of. tsc2/tsc1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013;187(6):663-5
   PubMed Web of Science ®Google Scholar
• Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mtor complex 1. Mol Cell 2010;39(2):171-83
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mtor and s6k1. Science 2013;339:1323-8
   PubMed Web of Science ®Google Scholar
• Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 2013;15(6):555-64
   PubMed Web of Science ®Google Scholar
• Menon S, Dibble CC, Talbott G, et al. Spatial control of the tsc. complex integrates insulin and nutrient regulation of mtorc1 at the lysosome. Cell 2014;156(4):771-85
   PubMed Web of Science ®Google Scholar
• Csibi A, Fendt SM, Li C, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013;153(4):840-54
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013;12(11):829-46
   PubMed Web of Science ®Google Scholar
• Dilling DF, Gilbert ER, Picken MM, et al. A current viewpoint of Lymphangioleimyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol 2012;46:1-5
   PubMed Web of Science ®Google Scholar
• DeRaedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 2011;20(3):400-13
   PubMed Web of Science ®Google Scholar